GALECTIN THERAPEUTICS INC. Interest Expense Nonoperating
GALECTIN THERAPEUTICS INC. (GALT) reported Interest Expense Nonoperating of $2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for the quarter ending 2026-06-30 was $2.00M, a 9.75% increase year-over-year.
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for the quarter ending 2026-03-31 was $1.99M, a 13.99% increase year-over-year.
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for the quarter ending 2025-12-31 was $1.94M, a 12.41% increase year-over-year.
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for the quarter ending 2025-09-30 was $1.82M, a 21.82% increase year-over-year.
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for fiscal 2025 was $7.33M, a 32.29% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for fiscal 2024 was $5.54M, a 98.42% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. interest expense nonoperating for fiscal 2023 was $2.79M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-08-14 | $3.99M 10-Q · filed 2026-08-14 | $5.93M derived: sum of 3 quarters · filed 2026-08-14 | $7.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.99M 10-Q · filed 2026-05-15 | $3.93M derived: sum of 2 quarters · filed 2026-05-15 | $5.75M derived: sum of 3 quarters · filed 2026-05-15 | $7.57M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.76M derived: sum of 2 quarters · filed 2026-03-31 | $5.58M derived: sum of 3 quarters · filed 2026-08-14 | $7.33M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.82M 10-Q · filed 2025-11-14 | $3.65M derived: sum of 2 quarters · filed 2026-08-14 | $5.39M 10-Q · filed 2025-11-14 | $7.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-14 | $3.57M 10-Q · filed 2026-08-14 | $5.29M derived: sum of 3 quarters · filed 2026-08-14 | $6.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.74M 10-Q · filed 2026-05-15 | $3.47M derived: sum of 2 quarters · filed 2026-05-15 | $4.96M derived: sum of 3 quarters · filed 2026-05-15 | $6.23M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.22M derived: sum of 2 quarters · filed 2026-03-31 | $4.49M derived: sum of 3 quarters · filed 2026-03-31 | $5.54M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.49M 10-Q · filed 2025-11-14 | $2.76M derived: sum of 2 quarters · filed 2025-11-14 | $3.81M 10-Q · filed 2025-11-14 | $4.66M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.27M 10-Q · filed 2025-08-14 | $2.32M 10-Q · filed 2025-08-14 | $3.17M derived: sum of 3 quarters · filed 2025-08-14 | $4.00M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.05M 10-Q · filed 2025-05-15 | $1.90M derived: sum of 2 quarters · filed 2025-05-15 | $2.73M derived: sum of 3 quarters · filed 2025-05-15 | $3.38M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $847.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.68M derived: sum of 2 quarters · filed 2025-03-31 | $2.33M derived: sum of 3 quarters · filed 2025-03-31 | $2.79M 10-K · filed 2025-03-31 |
| 2023-09-30 | $835.00K 10-Q · filed 2024-11-14 | $1.49M derived: sum of 2 quarters · filed 2024-11-14 | $1.95M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $650.00K 10-Q · filed 2024-08-13 | $1.11M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |